Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
The facility is expected to become operational by FY2028-29
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Subscribe To Our Newsletter & Stay Updated
